These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25363401)

  • 1. Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era.
    Sarkozy C; Camus V; Tilly H; Salles G; Jardin F
    Leuk Lymphoma; 2015 Jul; 56(7):1959-68. PubMed ID: 25363401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Lanic H; Kraut-Tauzia J; Modzelewski R; Clatot F; Mareschal S; Picquenot JM; Stamatoullas A; Leprêtre S; Tilly H; Jardin F
    Leuk Lymphoma; 2014 Apr; 55(4):817-23. PubMed ID: 23781925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Camus V; Lanic H; Kraut J; Modzelewski R; Clatot F; Picquenot JM; Contentin N; Lenain P; Groza L; Lemasle E; Fronville C; Cardinael N; Fontoura ML; Chamseddine A; Brehar O; Stamatoullas A; Leprêtre S; Tilly H; Jardin F
    Eur J Haematol; 2014 Jul; 93(1):9-18. PubMed ID: 24520908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Sarcopenia and Anemia Predicts Worse Outcome in Elderly Patients With Diffuse Large B-Cell Lymphoma.
    Liao PH; Chuang YH; Yang FS; Kuo CY; Ma MC; Liao CK; Wang MC
    In Vivo; 2023; 37(4):1847-1856. PubMed ID: 37369473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
    de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
    Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
    Xiao DY; Luo S; O'Brian K; Sanfilippo KM; Ganti A; Riedell P; Lynch RC; Liu W; Kahl BS; Cashen AF; Fehniger TA; Carson KR
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
    Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
    Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
    Boyle T; Connors JM; Gascoyne RD; Berry BR; Sehn LH; Bashash M; Spinelli JJ
    Br J Haematol; 2017 Aug; 178(3):442-447. PubMed ID: 28466570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
    Gobba S; Moccia AA; Gulden-Sala W; Conconi A; Diem S; Cascione L; Iacoboni G; Margiotta-Casaluci G; Aprile von Hohenstaufen K; Stathis A; Hitz F; Pinotti G; Gaidano G; Zucca E
    Hematol Oncol; 2018 Feb; 36(1):84-92. PubMed ID: 28621491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Park S; Han B; Cho JW; Woo SY; Kim S; Kim SJ; Kim WS
    Nutr Cancer; 2014; 66(2):225-33. PubMed ID: 24405259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
    Nakamura N; Hara T; Shibata Y; Matsumoto T; Nakamura H; Ninomiya S; Kito Y; Kitagawa J; Kanemura N; Goto N; Shiraki M; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
    Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study.
    Pénichoux J; Lanic H; Thill C; Ménard AL; Camus V; Stamatoullas A; Lemasle E; Leprêtre S; Lenain P; Contentin N; Kraut-Tauzia J; Fruchart C; Kammoun L; Damaj G; Farge A; Delette C; Modzelewski R; Vaudaux S; Pépin LF; Tilly H; Jardin F
    Ann Hematol; 2023 Jul; 102(7):1811-1823. PubMed ID: 37058153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.